It is made available under a CC-BY-NC-ND 4.0 International license .

1	SARS-CoV-2, the human placenta, and adverse perinatal outcomes
2	Rebecca L. LINN, MD, ¹ Markolline FORKPA, MPH, ² Rita LEITE, MD, ² Jessenia C.
3	GUERRERO, MD, ¹ Maria C. REYES, MD, ³ Lauren E. SCHWARTZ, MD, ³ Rebecca A.
4	SIMMONS, MD, ⁴ Samuel PARRY, MD, ² Thea N. GOLDEN, PharmD, PhD; ² Philadelphia, PA
5	¹ Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia
6	² Department of Obstetrics and Gynecology, Perelman School of Medicine at the University of
7	Pennsylvania
8	³ Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the
9	University of Pennsylvania
10	⁴ Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
11	
12	Disclosure statement: The authors do not have commercial associations that might pose
13	conflicts of interest, such as ownership, stock holdings, equity interests and consultant activities,
14	or patent-licensing situations.
15	
16	Sources of funding: This work was funded by a COVID-19 grant from the March of Dimes
17	(Parry and Simmons) and two mentored scientist awards from the University of Pennsylvania
18	(Golden, ES019851 – Translational Research Training Program in Environmental Sciences and
19	ES013508 – Mentored Scientist Transition Award funded by the Center for Excellence in
20	Environmental Toxicology). The sponsors did not participate in study design; in the collection,
21	analysis and interpretation of data; in the writing of this report; and in the decision to submit this
22	manuscript for publication.
23	
24	Corresponding author:
25	Samuel Parry, MD

26 Franklin Payne Professor, Department of Obstetrics and Gynecology

- 27 Perelman School of Medicine at the University of Pennsylvania
- 28 Philadelphia, PA 19104
- 29 parry@pennmedicine.upenn.edu
- 30
- 31 Number of text pages: 27
- 32 Tables: 6
- 33 **Figures:** 0
- 34 **Short title:** Placental pathology in COVID-19 cases
- 35
- 36

It is made available under a CC-BY-NC-ND 4.0 International license .

37 Abstract

38 The relationship among timing and severity of COVID-19 during pregnancy, placental pathology, and adverse pregnancy outcomes is not well understood. We conducted a prospective cohort 39 study of 497 pregnant patients with COVID-19 whose placentas underwent systematic 40 41 pathologic examination. The main exposure was timing of COVID-19 during pregnancy (first or 42 second versus third trimester). The primary outcome was composite placental pathology that included high grade maternal vascular malperfusion or greater than 25 percent perivillous fibrin 43 deposition. There were 63 patients who had the composite placental pathology outcome. In 44 45 adjusted analyses that controlled for maternal age, parity, active infection at delivery, interval from time of diagnosis to delivery and COVID-19 variant, timing of COVID-19 during pregnancy 46 was not associated with risk of the composite placental pathology outcome. Among secondary 47 48 COVID-19 related exposures we investigated, severity of disease and treatment for COVID-19 49 were associated with risk of the composite placental pathology outcome. In addition, patients with COVID-19 in the first nine months of the pandemic had the highest rate of the composite 50 51 placental pathology outcome. In this large cohort, placental vascular pathology was common 52 among COVID-19 cases but was unrelated to timing of COVID-19 during pregnancy or adverse 53 pregnancy outcomes. These findings suggest that uncomplicated COVID-19 during pregnancy does not require intensive fetal surveillance or detailed pathologic examination of the placenta 54 after delivery. 55

It is made available under a CC-BY-NC-ND 4.0 International license .

57 Introduction

58 Pregnancy appears to be a risk factor for severe disease with 2019 novel coronavirus disease (COVID-19). Immediately following the start of the pandemic case studies were published 59 reporting the increased incidence of maternal morbidity and mortality and adverse pregnancy 60 61 outcomes. We now have a better understanding of the increased risk of adverse outcomes following COVID-19 during pregnancy.¹⁻⁴ Smith et al. recently published a meta-analysis that 62 included over 13,000 pregnancies included in 12 studies across 12 countries.³ They found a 63 significantly greater risk of mortality, admission to intensive care unit, and other morbidities 64 among pregnant patients with COVID-19. They also found an increase in preterm birth and low 65 birth weight if the neonate was born to a patient with severe acute respiratory syndrome 66 coronavirus (SARS-CoV-2) infection during pregnancy. Many other reports associate COVID-19 67 68 with adverse pregnancy outcomes, including fetal growth restriction, hypertensive disorders of pregnancy, and fetal loss. ^{3,5-7} Most of these adverse pregnancy outcomes are attributed to 69 placental dysfunction,⁸⁻¹² but the effects of COVID-19 on placental pathology and placental 70 function have not been fully elucidated.¹³⁻¹⁷ 71

72

Placental pathology frequently is reported in pregnancies complicated by maternal SARS-CoV-2 73 infection. Vasculopathies and inflammation have been reported commonly in case series and 74 small cohort studies.^{13,14,17-21} Corbetta-Rastelli et al. recently conducted a relatively large cohort 75 study that included 138 placentas with infections during pregnancy.²² Similar to many smaller 76 studies published previously, they found a high incidence of maternal vascular malperfusion. 77 Unlike previous studies, this study evaluated the placenta following resolved SARS-CoV-2 78 infection. Interestingly, they found that placentas from pregnancies with resolved and active 79 80 infection had maternal vascular malperfusion. They also tested for a specific pathological 81 feature dependent on the gestational timing of infection, but did not find one. However, they did

It is made available under a CC-BY-NC-ND 4.0 International license .

report a higher frequency of placental pathology findings if the infection occurred before 20
 weeks of gestation.²²

84

This study aimed to identify factors contributing to the development of placenta pathology 85 86 following SARS-CoV-2 infection. We hypothesized that COVID-19 causes pathologic changes in 87 the placenta that are not related to timing or severity of clinical disease. To test this hypothesis, we assembled a large cohort of patients diagnosed with COVID-19 during pregnancy whose 88 placentas underwent comprehensive pathologic examination performed by an experienced 89 90 placental pathologist blinded to demographics and outcomes data for each patient. Our study 91 population includes patients of diverse racial and ethnic backgrounds, various gestational timing of infection, and a range of COVID-19 severity. The primary outcome we studied was a 92 93 composite of placental pathology findings (high grade maternal vascular malperfusion (MVM) 94 and/or presence of greater than 25 percent perivillous fibrin deposition), and exposures we compared included timing of infection during pregnancy (first or second trimester versus third 95 trimester), severity of COVID-19, and SARS-CoV-2 variants (four time periods of the COVID-19 96 97 pandemic). Secondary outcomes included adverse pregnancy outcomes stratified by presence 98 or absence of placental pathology.

99

100 Methods

This study was carried out with Institutional Review Board approval (protocol #843277) using
 clinical and pathologic material collected from the Hospital of the University of Pennsylvania
 (HUP), Philadelphia, Pennsylvania.

104

105 Selection of subjects

Women with a history of SARS-CoV-2 infection during pregnancy were identified either
 prospectively by a clinician/research coordinator present on the Labor and Delivery unit or

It is made available under a CC-BY-NC-ND 4.0 International license .

108 retrospectively by searching the HUP pathology database for placentas with the clinical history 109 of "COVID-19", "COVID-19 positive", "SARS-CoV-2", "SARS-CoV-2 positive", and "resolved COVID-19" from March 1, 2020 to February 28, 2022. During the study period, universal 110 screening via nasopharyngeal polymerase chain reaction (PCR) for SARS-CoV-2 was 111 112 performed for all admissions to the labor and delivery unit at our institution. The placentas of all patients with a positive SARS-CoV-2 test or a self-reported history of infection during pregnancy 113 were sent for routine gross and microscopic pathologic examination. COVID-19 cases for this 114 study were selected from this population based on the following criteria: singleton delivery at or 115 116 after 28 weeks gestational age (third trimester), and a documented positive SARS-CoV-2 PCR test during pregnancy. Additionally, cases with fetal congenital or genetic anomalies or a known 117 non-SARS-CoV-2 viral infection during this pregnancy (e.g., HIV, CMV, etc.) were excluded. In 118 119 order to compare rates of placenta pathology between COVID-19 cases and healthy controls, 120 we submitted placentas from a small group of healthy controls (N=26) who delivered during the same time period for routine gross and microscopic pathologic examination. 121

122

123 Clinical and demographic data collection

124 Maternal clinical characteristics were extracted from electronic medical records including maternal age at delivery, gravidity, parity, race/ethnicity, pre-gravid body mass index (kg/m²), 125 history of maternal disease (e.g. chronic hypertension, gestational hypertension, preeclampsia, 126 pre-gestational diabetes, or gestational diabetes), and maternal use of aspirin during pregnancy. 127 128 Obstetrical and neonatal outcomes that we studied included gestational age at delivery (weeks). preterm birth (before/after 37 weeks), birthweight, fetal sex, gestational hypertension, severe 129 maternal morbidity,²³ and severe neonatal morbidity.^{24,25} Birthweight z-scores were calculated 130 131 using research calculator references and standardized by both gestational age and newborn sex.^{26,27} In accordance with the American College of Obstetricians and Gynecologists definition 132 of severe maternal morbidity,²³ the composite severe maternal morbidity outcome was defined 133

134	as any (or multiple) of the following: (1) acute respiratory distress syndrome; (2) acute
135	myocardial infarction; (3) amniotic fluid embolism; (4) congestive heart failure; (5) sepsis/shock;
136	(6) hemorrhage; (7) eclampsia; (8) disseminated intravascular coagulation; (9) hysterectomy;
137	(10) ICU admission; (11) acute renal failure; (12) assisted ventilation (intubation); and (13)
138	death. There were no maternal deaths. In accordance with the Maternal-Fetal Medicine Units
139	Network criteria for severe neonatal morbidity, ^{24,25} the composite severe neonatal morbidity
140	outcome was defined as any (or multiple) of the following: (1) respiratory distress syndrome; (2)
141	transient tachypnea of the newborn; (3) sepsis; (4) assisted ventilation; (5) seizure; (6) grade 3
142	or 4 intraventricular hemorrhage; (7) necrotizing enterocolitis; (8) NICU admission; and (9)
143	CPAP or supplemental oxygen.
144	
145	The severity of maternal COVID19 disease was categorized based on National Institutes of
146	Health and Society for Maternal-Fetal Medicine criteria initially issued in 2020:
147	1 - Asymptomatic Infection: Individuals who test positive for SARS-CoV-2 by virologic
148	testing using a molecular diagnostic test but have no symptoms.
149	2 - Mild Illness: Individuals who have any of the various signs and symptoms of COVID
150	19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of
151	breath, dyspnea, or abnormal chest imaging.
152	3 - Moderate Illness: Individuals who have evidence of lower respiratory disease by
153	clinical assessment or imaging and a saturation of oxygen $(SpO_2) \ge 94\%$ on room air at
154	sea level.
155	4 - Severe Illness: Individuals who have respiratory frequency >30 breaths per minute,
156	SpO ₂ <94% on room air at sea level, ratio of arterial partial pressure of oxygen to
157	fraction of inspired oxygen (PaO ₂ /FiO ₂) <300 mmHg, or lung infiltrates >50%
158	5 - Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple
159	organ dysfunction.

1	۶n
т	00

161	The gestational age at the time of positive S	SARS-CoV-2 test was collected and the days from	
162	diagnosis to delivery were calculated. Mate	rnal COVID-19 status at delivery was further	
163	categorized as active (positive test result at	the time or within 14 days of delivery) or resolved	
164	(positive test result > 14 days before date o	f delivery). Infants delivered to patients with active	
165	COVID-19 at the time of delivery were routi	nely tested via nasopharyngeal swab PCR test for	
166	SARS-CoV-2 at 24 and 48 hours of life. If a	n infant was tested for SARS-CoV-2 after delivery,	
167	these results were also collected.		
168			
169	A publicly available surveillance sequencing	g dashboard of SARS-CoV-2 variants circulating in	
170	the Philadelphia region since March 2020 w	vas utilized to categorize patients into one of four	
171	variant time periods (City of Philadelphia De	epartment of Public Health,	
172	(https://microb120.med.upenn.edu/data/SA	RS-CoV-2/). As our institution is one of the main	
173	contributors to this dashboard and a majorit	ty of patient's delivering at our institution are located	
174	within the geographic region covered by thi	s collaborative effort, these data should represent	
175	our patient population. Based on the predo	minant variants present, patients were categorized	
176	based on the date of their positive SARS-C	oV-2 PCR test as follows:	
177	Pre-variants of COVID-19 (pVOC):	March 2020 – December 2020	
178	Alpha:	January 2021 – May 2021	
179	Delta:	June 2021 – December 2021	
180	Omicron:	January 2022 – February 2022	
181			
182	Placenta pathologic data collection		
183	All placentas were examined in the patholo	gy department at HUP utilizing a systematic protocol,	
184	including recording the trimmed placental weight, membrane insertion site, gross appearance,		
185	dimensions of the placental disc, and the in	sertion, length, and diameter of the umbilical cord.	

It is made available under a CC-BY-NC-ND 4.0 International license .

186	Histologic samples included sections of membranes, umbilical cord, and at least three full-
187	thickness sections of non-lesion placental parenchyma. The placentas from COVID-19 cases
188	were fixed in 10% buffered formalin for at least 24 hours prior to examination. Macroscopic and
189	microscopic lesions were described primarily according to the Amsterdam Placental Workshop
190	Group 2014 classification and further defined as per Table 1 . ²⁸⁻³⁰ A composite of high grade
191	MVM and/or presence of greater than 25 percent perivillous fibrin deposition was the primary
192	placental pathology outcome we investigated. Microscopic examination was performed by a
193	single perinatal pathologist for all placentas (R.L.L.) blinded to exposures (i.e., timing and
194	severity of COVID-19) and clinical outcomes. Subsequently, a second review on a subset of 32
195	placentas was performed to assess inter-observer reliability. Slides were reviewed
196	independently by two pathologists (R.L.L. and J.C.G.) to assess for the presence or absence of:
197	chronic inflammation including chronic villitis and chronic histiocytic intervillositis; fetal vascular
198	malperfusion (FVM) including fetal vascular thrombi, avascular villi and villous stromal vascular
199	karyorrhexis; MVM including decidual vasculopathy, villous infarction, accelerated villous
200	maturation, distal villous hypoplasia; and increased perivillous fibrin deposition.
201	
202	Statistical Analysis
203	Statistical analyses were performed with SAS 9.4 for Windows. An alpha level of 0.05 was used
204	to determine statistical significance; Bonferroni correction was used for multiple comparisons.
205	
206	Timing of COVID-19 during pregnancy (first or second trimester versus third trimester) was the
207	main exposure and a composite of placental pathology, defined as the presence of high grade
208	MVM and/or presence of greater than 25 percent perivillous fibrin deposition, was the primary
209	outcome.

It is made available under a CC-BY-NC-ND 4.0 International license .

211	Patient demographics included maternal age (years); race (Black/African American versus
212	Caucasian/Asian/Other); gestational age (weeks); fetal sex (male versus female); chronic
213	hypertension; diabetes; active infection at delivery; COVID-19 treatment; COVID-19 vaccination
214	preceding COVID-19 diagnosis; COVID-19 severity (asymptomatic/mild versus
215	moderate/severe/critical); COVID-19 variant (pVOC/alpha/delta/omicron); and infection
216	exposure window (days from delivery).
217	
218	Summary statistics were computed as frequencies and proportions for all categorical variables.
219	Maternal age and exposure window were summarized with mean and standard deviation.
220	Chi-square test for independence, Student's t-test, and Wilcoxon ranked sum test were
221	performed to examine bivariable associations between timing of exposure and patient
222	characteristics. All characteristics with P<0.05 were considered potential confounders and
223	included in an adjusted logistic regression model.
224	
225	Simple logistic regression was first performed to find the crude association between timing of
226	COVID-19 during pregnancy (first or second trimester versus third trimester) and the composite
227	placental pathology outcome. Next, potential confounding variables were placed in a regression
228	model for adjusted estimates of the association between timing of infection and odds of the
229	composite placental pathology outcome.
230	
231	Results
232	A total of 497 placentas from patients who had COVID-19 during pregnancy were evaluated for
233	this study. Within this cohort, 156 patients had COVID-19 during the first or second trimester
234	and 341 patients had COVID-19 during the third trimester (primary exposure). Sixty-three

patients had the composite placental pathology outcome (high grade MVM and/or presence of

greater than 25 percent perivillous fibrin deposition), and 434 did not have the primary outcome.

It is made available under a CC-BY-NC-ND 4.0 International license .

237	Demographic characteristics and secondary COVID-19 related exposures were compared
238	between patients with COVID-19 in the first or second trimester versus patients with COVID-19
239	in the third trimester (timing of COVID-19 during pregnancy, primary exposure of interest, Table
240	2). Among the demographic characteristics we studied, maternal age was greater and patients
241	were more likely to be multiparous among the group with COVID-19 in the first or second
242	trimester. In accordance with study design, COVID-19 at delivery was less common and the
243	interval from COVID-19 diagnosis to delivery was greater among the group with COVID-19 in
244	the first or second trimester.

245

In unadjusted analyses, timing of COVID-19 during pregnancy was not associated with 246 247 increased risk of the composite placental pathology outcome - 22/156 (14.1 percent) patients 248 with COVID-19 in the first or second trimester compared to 41/341 (12.0 percent) with COVID-249 19 in the third trimester (P=0.518, OR 1.20, 95 percent Cl 0.69, 2.10; **Table 3**). Maternal age, 250 parity, active infection at delivery, interval from time of diagnosis to delivery, and COVID-19 251 variant were associated with the primary exposure, trimester of infection (Table 2). Hence, in 252 adjusted analyses, we controlled for these variables and determined timing of COVID-19 during 253 pregnancy was not associated with odds of composite placental pathology in this sample (P=0.547, OR 1.33, 95 percent CI 0.53, 3.34). 254

255

Among the secondary COVID-19 related exposures we investigated, severity of disease (moderate/severe/critical versus asymptomatic/mild) and treatment for COVID-19 (yes/no) were associated with risk of the composite placental pathology outcome (P<0.05), while COVID-19 vaccination (yes/no) and COVID-19 active at delivery (yes/no positive SARS-CoV-2 PCR at delivery admission) were not associated with the composite placental pathology outcome. Although there were not statistically different rates of the composite placental pathology outcome among the four SARS-CoV-2 variants (P=0.070, **Table 3**), we did observe a trend

It is made available under a CC-BY-NC-ND 4.0 International license .

263 toward greater rates of the composite placental pathology outcome in the earlier epochs during the pandemic - pVOC (March 2020 - December 2020, 18.2 percent), Alpha (January 2021 -264 May 2021, 10.5 percent), Delta (June 2021 – December 2021, 12.6 percent), Omicron (January 265 2022 - February 2022, 7.3 percent). 266 267 After correcting for multiple comparisons (Bonferroni significance = 0.008 for analysis of six 268 269 secondary outcomes), no secondary obstetrical/neonatal outcomes were associated with timing 270 of COVID-19 during pregnancy (**Table 4**). In stratified analyses, we found that timing of COVID-271 19 during pregnancy in patients with the composite placental pathology was not associated with

risk of secondary maternal/neonatal outcomes, while timing of COVID-19 during pregnancy in

273 patients without the composite placental pathology was associated with risk of spontaneous

preterm birth (15/134 [11.2 percent] patients with COVID-19 in the first or second trimester

versus 12/300 [4.0 percent] patients with COVID-19 in the third trimester; P=0.004, Table 5).

276

277 Timing of COVID-19 during pregnancy and secondary COVID-19 exposures were not 278 associated with other individual placental pathology outcomes that we investigated (Table 6. 279 P>0.05 for all outcomes). In order to compare rates of placenta pathology between COVID-19 280 cases and healthy controls, we analyzed placentas from a small group of healthy controls (N=26) who delivered during the same time period (March 1, 2020 to February 28, 2022). 281 Although low grade MVM or FVM was observed in 7/26 controls (26.9 percent), none of the 282 283 placentas from 26 healthy controls had the composite placental pathology outcome (high grade MVM or presence of greater than 25 percent perivillous fibrin deposition). 284

285

The previously collected data were not changed by the results of our interobserver reliability
assessment. Interobserver agreement between the two pathologists ranged from substantial to

It is made available under a CC-BY-NC-ND 4.0 International license .

almost perfect for the two components of the composite placental pathology outcome: kappa =
 0.761 for >25 percent perivillous fibrin deposition, kappa = 0.930 for high grade MVM.³¹

290

291 Discussion

292 In this large cohort, the composite placental pathology outcome (high grade MVM or presence 293 of greater than 25 percent perivillous fibrin deposition) was relatively common among COVID-19 cases but was unrelated to timing of COVID-19 during pregnancy (first or second trimester 294 295 versus third trimester) and adverse pregnancy outcomes. Among the secondary COVID-19 296 related exposures we investigated, severity of disease (moderate/severe/critical versus asymptomatic/mild) and treatment for COVID-19 (yes/no) were associated with risk of the 297 composite placental pathology outcome. Spontaneous preterm birth occurred more frequently 298 299 among patients with COVID-19 in the first or second trimester compared to COVID-19 in the 300 third trimester, but in stratified analyses, we discovered that increased rates of spontaneous 301 preterm births were restricted to patients with COVID-19 in the first or second trimester who did 302 not have the composite placental pathology. An interesting trend we observed is that the 303 composite placental pathology outcome occurred most frequently among pregnant patients who 304 had COVID-19 early in the pandemic: March – December 2020 (pre-variants of COVID-19, 25/137, 18.2 percent) versus January – February 2022 (Omicron, 8/110, 7.3 percent). 305 306

Early reports during the COVID-19 pandemic showed low rates of placental infection with SARS-CoV-2 but high rates of placental pathology, including MVM, FVM, and villitis of unknown origin.¹³⁻¹⁷ A later meta-analysis that included 56 studies and pathological examination of 1,008 placentas from patients who had COVID-19 largely at the time of delivery revealed rates of MVM, FVM, and perivillous fibrin deposition that ranged from 25 to 33 percent, and these rates were higher in cases compared to healthy controls who did not have COVID-19 during pregnancy.³² Placental pathology is extensive in pregnancies complicated by acute SARS-CoV-

It is made available under a CC-BY-NC-ND 4.0 International license .

2 infection, although less is known about placental pathology following a resolved infection
during pregnancy. Here we report similar placental pathology in pregnancies with a resolved
SARS-CoV-2 infection, even months after infection. This confirms the previous report by
Corbetta-Rastelli et al in a smaller cohort.²²

318

While asymptomatic infections cause placental pathology, it has previously been reported that pathology is independent of severity of disease.³² This conclusion is limited by the small cohorts reported thus far. In our cohort, we discovered that patients with a moderate, severe, or critical clinical presentation have a higher incidence of the composite placental pathology outcome than patients with an asymptomatic or mild case. We propose the difference between our study and others is due to the large sample size and assessment by the same team of pathologists.

325

326 Placental pathology is not correlated with adverse pregnancy outcomes. Other investigators studying COVID-19 in Philadelphia found a lack of correlation between preterm birth and 327 placental pathology and suggested placental pathology and preterm birth are caused by 328 divergent pathways.³³ We found that the risk of preterm birth is highest in COVID-19 patients 329 330 without the composite placental pathology. These investigators also reported higher rates of placental vascular pathology in patients with COVID-19 but not a COVID-19 vaccine during 331 pregnancy compared to controls.³³ We found a trend toward higher rates of the composite 332 placenta pathology in patients who did not receive the COVID-19 vaccine compared to patients 333 334 who did receive the COVID-19 vaccine (P=0.144), but the unvaccinated cases probably occurred earlier in the pandemic when the composite placental pathology outcome was 335 observed most frequently. 336

It is made available under a CC-BY-NC-ND 4.0 International license .

338 The most recent studies of placental pathology in COVID-19 cases demonstrate high rates of 339 placental pathology, and these investigators recommend that COVID-19 is a risk factor that requires close monitoring during pregnancy.^{34,35} Our data do not support these 340 recommendations. We found that the composite placental pathology was unrelated to adverse 341 342 pregnancy outcomes, and patients with COVID-19 early in pregnancy did not have higher rates of small for gestational age neonates (birthweight <10th percentile), preterm birth, the composite 343 neonatal outcome, gestational hypertension, or severe maternal morbidity compared to patients 344 with COVID-19 during the third trimester. Hence, we do not believe that uncomplicated COVID-345 346 19 during pregnancy requires intensive fetal surveillance or detailed pathological examination of placentas after delivery. 347 348 349 The reasons for high-rates of placental pathology in COVID-19 cases (63/497 [12.7 percent] in 350 our cohort had high grade MVM or presence of greater than 25 percent perivillous fibrin deposition) remain poorly understood. COVID-19 induces systemic pro-inflammatory and pro-351 coagulant effects, so future work may focus on inflammatory mediators and coagulation factors 352 353 that affect the placenta in COVID-19 cases. 354 355 Our study had several notable strengths and limitations. We believe this is the largest single center cohort of COVID-19 cases during pregnancy in which placental pathology was examined 356 357 in detail. The study population is representative of COVID-19 cases in large medical centers 358 that employed universal SARS-CoV-2 screening for patients admitted to labor and delivery units during the pandemic, and careful clinical phenotyping was performed. The primary pathologist 359 was blinded to COVID-19 factors (i.e., timing and severity of disease) and pregnancy outcomes. 360 361 Unfortunately, the study was limited by the small number of unaffected control placentas that

362 were evaluated during the pandemic, because placentas from healthy patients with normal

363 pregnancy outcomes are not routinely sent to pathologists for evaluation. In addition, the

It is made available under a CC-BY-NC-ND 4.0 International license .

primary exposure we evaluated (COVID-19 during the first or second trimester) occurred in only
156 of the total 497 patients within the overall cohort.

366

We conclude that placental vascular abnormalities occur in a large number of COVID-19 cases 367 368 but do not appear to be related to timing of COVID-19 during pregnancy. However, COVID-19 severity and maternal race influence the incidence of placental pathology. In stratified analyses 369 370 among patients with COVID-19 early in pregnancy, the composite placental pathology outcome 371 was not associated with higher rates of severe maternal morbidity or the composite adverse neonatal outcome. Hence, we do not believe that intensive fetal surveillance (i.e., serial non-372 stress tests or biophysical profiles) and detailed examination of placental pathology are 373 374 warranted in otherwise uncomplicated cases of COVID-19 during pregnancy. Additional 375 research is needed to understand why these high rates of placental vascular abnormalities 376 occur in COVID-19 cases.

It is made available under a CC-BY-NC-ND 4.0 International license .

378 **References**

- 1. Brandt JS, Hill J, Reddy A, et al. Epidemiology of coronavirus disease 2019 in
- 380 pregnancy: risk factors and associations with adverse maternal and neonatal outcomes.
- 381 Am J Obstet Gynecol 2020.
- Rasmussen SA, Jamieson DJ. COVID-19 and Pregnancy. Infect Dis Clin North Am
 2022;36:423-33.
- 384 3. Smith ER, Oakley E, Grandner GW, et al. Adverse maternal, fetal, and newborn

385 outcomes among pregnant women with SARS-CoV-2 infection: an individual participant

data meta-analysis. BMJ Glob Health 2023;8.

- 387 4. Smith ER, Oakley E, Grandner GW, et al. Clinical risk factors of adverse outcomes
- among women with COVID-19 in the pregnancy and postpartum period: a sequential,

prospective meta-analysis. Am J Obstet Gynecol 2023;228:161-77.

- 390 5. Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of
- 391 preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol
- 392 2022;226:68-89 e3.
- Kazemi SN, Hajikhani B, Didar H, et al. COVID-19 and cause of pregnancy loss during
 the pandemic: A systematic review. PLoS One 2021;16:e0255994.
- Metz TD, Clifton RG, Hughes BL, et al. Disease Severity and Perinatal Outcomes of
 Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol
 2021;137:571-80.
- 8. Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed:
- from spiral arteries remodeling to the great obstetrical syndromes. Am J Obstet Gynecol
 2019;221:437-56.
- 401 9. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of

402 placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic

403 pregnancies. Br J Obstet Gynaecol 1994;101:669-74.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 404 10. Parry S, Sciscione A, Haas DM, et al. Role of early second-trimester uterine artery
- 405 Doppler screening to predict small-for-gestational-age babies in nulliparous women. Am
- 406 J Obstet Gynecol 2017;217:594 e1- e10.
- 407 11. Reddy UM. Prediction and prevention of recurrent stillbirth. Obstet Gynecol
- 408 2007;110:1151-64.
- 409 12. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science
 410 2005;308:1592-4.
- 411 13. Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers: Preliminary
 412 Findings. Pediatr Dev Pathol 2020;23:177-80.
- 413 14. Cribiu FM, Erra R, Pugni L, et al. Severe SARS-CoV-2 placenta infection can impact

414 neonatal outcome in the absence of vertical transmission. J Clin Invest 2021.

- Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. A mechanistic analysis placental
 intravascular thrombus formation in COVID-19 patients. Ann Diagn Pathol
- 417 2020;46:151529.
- 418 16. Patberg ET, Adams T, Rekawek P, et al. Coronavirus disease 2019 infection and
- 419 placental histopathology in women delivering at term. Am J Obstet Gynecol 2020.
- 420 17. Sharps MC, Hayes DJL, Lee S, et al. A structured review of placental morphology and
 421 histopathological lesions associated with SARS-CoV-2 infection. Placenta 2020;101:13-
- 422 29.
- 18. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental Pathology
 in COVID-19. Am J Clin Pathol 2020;154:23-32.
- 425 19. Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe
- 426 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy:
- 427 Measures of Immunity and Placental Histopathology. Obstet Gynecol 2021;138:281-3.
- 428 20. Wong YP, Khong TY, Tan GC. The Effects of COVID-19 on Placenta and Pregnancy:
- 429 What Do We Know So Far? Diagnostics (Basel) 2021;11.

430	21.	Joshi B, Chandi A, Srinivasan R, et al. The placental pathology in Coronavirus disease
431		2019 infected mothers and its impact on pregnancy outcome. Placenta 2022;127:1-7.
432	22.	Corbetta-Rastelli CM, Altendahl M, Gasper C, Goldstein JD, Afshar Y, Gaw SL. Analysis
433		of placental pathology after COVID-19 by timing and severity of infection. Am J Obstet
434		Gynecol MFM 2023;5:100981.
435	23.	American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal
436		Medicine, Kilpatrick SK, Ecker JL. Severe maternal morbidity: screening and review. Am
437		J Obstet Gynecol 2016;215:B17-22.
438	24.	Chauhan SP, Rice MM, Grobman WA, et al. Neonatal Morbidity of Small- and Large-for-
439		Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies. Obstet Gynecol
440		2017;130:511-9.
441	25.	Manuck TA, Rice MM, Bailit JL, et al. Preterm neonatal morbidity and mortality by
442		gestational age: a contemporary cohort. Am J Obstet Gynecol 2016;215:103 e1- e14.
443	26.	Chou JH, Roumiantsev S, Singh R. PediTools Electronic Growth Chart Calculators:
444		Applications in Clinical Care, Research, and Quality Improvement. J Med Internet Res
445		2020;22:e16204.
446	27.	Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth
447		chart for preterm infants. BMC Pediatr 2013;13:59.
448	28.	Freedman AA, Keenan-Devlin LS, Borders A, Miller GE, Ernst LM. Formulating a
449		Meaningful and Comprehensive Placental Phenotypic Classification. Pediatr Dev Pathol
450		2021;24:337-50.
451	29.	Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental Lesions:
452		Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med
453		2016;140:698-713.

- 454 30. Redline RW, Ravishankar S, Bagby CM, Saab ST, Zarei S. Four major patterns of
- 455 placental injury: a stepwise guide for understanding and implementing the 2016
- 456 Amsterdam consensus. Mod Pathol 2021;34:1074-92.
- 457 31. Sierra F, Cardenas A. Evidence-based medicine (EBM) in practice: agreement between
- 458 observers rating esophageal varices: how to cope with chance? Am J Gastroenterol
- 459 2007;102:2363-6.
- 460 32. Di Girolamo R, Khalil A, Alameddine S, et al. Placental histopathology after SARS-CoV-
- 461 2 infection in pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol
 462 MFM 2021;3:100468.
- 463 33. Boelig RC, Aghai ZH, Chaudhury S, Kazan AS, Chan JSY, Bergmann-Leitner E. Impact
- 464 of COVID-19 disease and COVID-19 vaccination on maternal or fetal inflammatory
- 465 response, placental pathology, and perinatal outcomes. Am J Obstet Gynecol
- 466 2022;227:652-6.
- 467 34. Milot C, Koch A, Averous G, Mayeur S, Deruelle P. Development of placental lesions
 468 after recovery from COVID-19 during pregnancy: case-control study. BJOG
- 469 2023;130:949-58.
- 470 35. Montans Araujo J, Suy Franch A, Garcia Ruiz I, Maiz N, Garcia Aguilar E, Hidalgo
- 471 Bermejo FJ. Impact of COVID-19 disease on placental histopathology. PLAXAVID study.
- 472 Histol Histopathol 2023:18639.
- 473
- 474

It is made available under a CC-BY-NC-ND 4.0 International license .

- 475 **Table 1.** Macroscopic and microscopic placental lesions (Amsterdam Placental Workshop
- 476 Group 2014 classification).²⁴ A composite of high grade maternal vascular malperfusion (MVM)
- 477 or presence of greater than 25 percent perivillous fibrin deposition was the primary placental
- 478 pathology outcome we analyzed.

Variable	Lesions included	Definition of grading
Chronic	Membranes/chorionic plate:	High-grade: <a>2 compartments with
inflammation	chronic chorionitis, chronic	chronic inflammation
	amnionitis	Low-grade: 1 compartment with
	Basal plate: chronic deciduitis with	chronic inflammation
	plasma cells	<u>None</u> : no compartments with
	<u>viiii</u> : chronic viiius, intravilious	chronic initammation
	Intervillous space: chronic	
	histiocytic intervillositis (≥2%	
	involvement of intervillous space)	
	Fetal: eosinophilic T-cell vasculitis	
Fetal vascular	Fetal vascular thrombi or intramural	High grade: ≥2 fetal chorionic or
malperfusion	fibrin deposition in umbilical,	stem villous vascular thrombi or a
(FVM)	chorionic, or stem villous vessel; at	total of ≥45 avascular villi over 3
	least 3 foci of avascular villi and/or	sections examined
	villous stromal vascular	Low grade: any FVM lesions
	karyorrhexis (≥3 villi/focus)	insufficient for a high-grade
		categorization
Maternal vaccular	Decidual vasculariathy: fibringid	<u>None</u> . No retai vascular resions
malperfusion	<u>Decidual vasculopatity</u> . Ibilitolu pecrosis/acute atherosis, persistent	<u>right grade</u> . accelerated villous
(MVM)	muscularization of basal plate	placental weight $<10^{\text{th}}$ percentile
	arterioles mural hypertrophy of	multiple villous infarcts or distal
	membrane arterioles, basal	villous hypoplasia
	decidual vascular thrombus,	Low grade: any MVM lesions
	chronic decidual perivasculitis	insufficient for a high-grade
	Villous infarction	categorization
	Accelerated villous maturation	<u>None</u> : no MVM lesions ²⁵
	including increased syncytial knots	
	for gestational age	
	Distal villous hypoplasia	
	Changes consistent with	
	<u>hemorrhage/hematoma</u>	
Perivillous fibrin	Increased perivillous fibrin in the	>10% perivillous fibrin deposition
deposition	intervillous space (more than	$\geq 25\%$ perivillous fibrin deposition
	expected for gestational age)	

479

It is made available under a CC-BY-NC-ND 4.0 International license .

- 481 **Table 2.** Demographics and secondary COVID-19 exposures comparing patients with
- 482 COVID-19 in the first or second trimester and patients with COVID-19 in the third trimester
- 483 (primary exposure). Chi-square and Fisher's exact tests were used to find P-values for
- 484 categorical variables. Student's t-test and Wilcoxon ranked sum tests were used to find P-values
- 485 for continuous measures. pVOC = pre-variants of COVID-19.

		First or Second	Third		
Variable		Trimester	Trimester	Р	
Vallable		COVID-19	COVID-19	value	
		(N=156)	(N=341)		
Maternal age (yr)	Mean (SD)	30.3 (5.92)	28.1 (6.26)	<0.001	
Parity	Nulliparous	50 (26.2%)	141 (73.8%)	0 0/8	
T anty	Multiparous	106 (34.6%)	200 (65.4%)	0.040	
Fotal sox	Male	84 (32.6%)	174 (67.4%)	0 550	
Fetal Sex	Female	72 (30.1%)	167 (69.9%)	0.559	
Maternal race	Black/African Am	104 (29.7%)	246 (70.3%)	0 1 2 2	
Maternal race	White/Asian/other	52 (36.9%)	89 (63.1%)	0.125	
Chronic hyportonaion	No	139 (31.1%)	308 (68.9%)	0 675	
Chronic hypertension	Yes	17 (34.0%)	33 (66.0%)	0.075	
Diabataa	No	139 (31.1%)	308 (68.9%)	0.675	
Diabeles	Yes	17 (34.0%)	33 (66.0%)		
$O_{\text{basity}}(\mathbf{PM} > 10)$	No	83 (29.0%)	203 (71.0%)	0 107	
Obesity (BMI <u>></u> 40)	Yes	70 (34.7%)	132 (65.3%)	0.107	
COVID 10 at delivery	No	149 (53.6%)	129 (46.4%)	~0 001	
COVID-19 at delivery	Yes	7 (3.2%)	212 (96.8%)	NU.UU	
Interval from diagnosis to	Mean (SD)	118 5 (52 8)	17 2 (22 7)	<0 001	
delivery (days)		110.0 (02.0)		-0.001	
Treatment for COV/ID-19	No	143 (31.5%)	311 (68.5%)	0 695	
	Yes	12 (28.6%)	30 (71.4%)	0.000	
$COVID_{-}19$ severity	Asymptomatic/mild	137 (30.5%)	312 (69.5%)	0 316	
	Mod/severe/critical	17 (37.8%)	28 (62.2%)	0.010	
COVID-19 vaccination	No	119 (30.4%)	272 (69.6%)	0 379	
	Yes	37 (34.9%)	69 (65.1%)	0.075	
	pVOC	59 (43.1%)	78 (56.9%)		
$SARS_CoV_2$ variant	Alpha	23 (30.3%)	53 (69.7%)	<0 001	
	Delta	57 (32.8%)	117 (67.2%)	-0.001	
	Omicron	17 (15.5%)	93 (84.5%)		

It is made available under a CC-BY-NC-ND 4.0 International license .

- 488 **Table 3.** Unadjusted analyses of rates of composite placental pathology (primary
- 489 outcome) compared between primary and secondary exposure groups. Chi-square tests were
- 490 used to find P values. pVOC = pre-variants of COVID-19.

Variable		Absence of composite placental pathology outcome (N=434)	Presence of composite placental pathology outcome (N=63)	P value
Timing of	1 st /2 nd trimester	134 (85.9%)	22 (14.1%)	0.518
	3 rd trimester	300 (88.0%)	41 (12.0%)	
COVID-19 at	NO	241 (86.7%)	37 (13.3%)	0.633
delivery	Yes	193 (88.1%)	26 (11.9%)	
Treatment for	No	401 (88.3%)	53 (11.7%)	0.024
COVID-19	Yes	32 (76.2%)	10 (23.8%)	0.024
COVID-19	Asymptomatic/mild	397 (88.4%)	52 (11.6%)	0.040
severity	Mod/severe/critical	35 (77.8%)	10 (22.2%)	0.040
	pVOC	112 (81.8%)	25 (18.2%)	
SARS-CoV-2	Alpha	68 (89.5%)	8 (10.5%)	0.070
variant	Delta	152 (87.4%)	22 (12.6%)	0.070
	Omicron	102 (92.7%)	8 (7.3%)	
COVID-19	No	337 (86.2%)	54 (13.8%)	0.144
vaccination	Yes	97 (91.5%)	9 (8.5%)	0.144

491

It is made available under a CC-BY-NC-ND 4.0 International license .

493 **Table 4.** Obstetrical and neonatal outcomes. SGA=small for gestational age (birthweight

494 <10th percentile, birthweight z-scores were calculated using research calculator references and

standardized by both gestational age and newborn sex;^{21,22} SPTB=spontaneous preterm birth;

- 496 PTB=preterm birth. P values were calculated by chi-square test; Bonferroni significance = 0.008
- 497 for analysis of six secondary outcomes.

Outcome		First or Second Trimester COVID-19 (N=156)	Third Trimester COVID-19 (N=341)	P value
SGA	BW>10 th percentile	139 (90.8%)	287 (84.7%)	0.062
	BW<10 th percentile	14 (8.2%)	52 (15.3%)	0.002
Composite neonatal	No	123 (78.8%)	274 (80.4%)	0 698
outcome	Yes	33 (21.2%)	67 (19.6%)	0.000
SPTB <37 wk	No	140 (89.7%)	326 (95.6%)	0.012
	Yes	16 (10.3%)	15 (4.4%)	01012
Medically indicated	No	137 (87.8%)	313 (91.8%)	0 161
PTB <37 wk	Yes	19 (12.2%)	28 (8.2%)	01101
Gestational	No	121 (77.6%)	253 (74.2%)	0 4 1 9
hypertension	Yes	35 (22.4%)	88 (25.8%)	0.110
Severe maternal	No	146 (93.6%)	310 (90.9%)	0.313
morbidity	Yes	10 (6.4%)	31 (9.1%)	0.010

498

500	Table 5.	Stratified analys	ses comparing	risk of adverse	pregnancy outcomes	based on
					1	

- 501 timing of COVID-19 during pregnancy (first or second trimester versus third trimester) in patients
- 502 with or without the primary placental pathology outcome (high grade maternal vascular
- 503 malperfusion (MVM) or presence of greater than 25 percent perivillous fibrin deposition).
- 504 SGA=small for gestational age (birthweight <10th percentile, birthweight z-scores were
- 505 calculated using research calculator references and standardized by both gestational age and
- newborn sex;^{21,22} SPTB=spontaneous preterm birth; PTB=preterm birth. P values were
- 507 calculated by chi-square test or Fisher's exact test (if \leq 5 samples in a cell).
- 508

Patients with primary placental pathology outcome (N=63)					
Outcome		First or Second Trimester COVID- 19 (N=22)	Third Trimester COVID-19 (N=41)	P value	
SGA	BW>10 th percentile BW<10 th percentile	17 (77.3%) 5 (22.7%)	25 (61.0%) 16 (39.0%)	0.265	
Composite neonatal outcome	No Yes	13 (59.1%) 9 (40.9%)	28 (68.3%) 13 (31.7%)	0.465	
SPTB <37 wk	No Yes	21 (95.4%) 1 (4.6%)	38 (92.7%) 3 (7.3%)	1.000	
Medically indicated PTB <37 wk	No Yes	14 (63.6%) 8 (36.4%)	33 (80.5%) 8 (19.5%)	0.143	
Gestational hypertension	No Yes	14 (63.6%) 8 (36.4%)	26 (63.4%) 15 (36.6%)	0.986	
Severe maternal morbidity	No Yes	20 (90.9%) 2 (9.1%)	35 (85.4%) 6 (14.6%)	0.702	
Patients without primary placental pathology outcome (N=434)					
Outcome		First or Second Trimester COVID- 19 (N=134)	Third Trimester COVID-19 (N=300)	P value	

It is made available under a CC-BY-NC-ND 4.0 International license .

SGA	BW>10th percentile	122 (93.1%)	262 (87.9%)	0 105
00/1	BW<10th percentile	9 (6.9%)	36 (12.1%)	0.100
Composite neonatal	No	110 (82.1%)	246 (82.0%)	0 982
outcome	Yes	24 (17.9%)	54 (18.%)	0.002
SPTB <37 wk	No	119 (88.8%)	288 (96.0%)	0 004
	Yes	15 (11.2%)	12 (4.0%)	0.004
Medically indicated	No	123 (91.8%)	280 (93.3%)	0 564
PTB <37 wk	Yes	11 (8.2%)	20 (6.7%)	0.004
Gestational	No	107 (79.8%)	227 (75.7%)	0 339
hypertension	Yes	27 (20.2%)	73 (24.3%)	0.000
Severe maternal	No	126 (94.0%)	275 (91.7%)	0.391
morbidity	Yes	8 (6.0%)	25 (8.3%)	0.001

509

It is made available under a CC-BY-NC-ND 4.0 International license .

511 **Table 6.** Secondary placenta pathology outcomes.

Outcome	Exposure	Unadjusted P value	Bonferroni P value ¹
	Timing of COVID-19 (trimester)	0.580	1
High grade fetal vessuler	COVID-19 at delivery	0.812	1
	Treatment for COVID-19	0.7518	1
maipenusion	COVID-19 severity	0.180	0.901
	SARS-CoV-2 variant	0.186	0.932
	Timing of COVID-19 (trimester)	0.554	1
	COVID-19 at delivery	0.913	1
Fetal vascular thrombi	Treatment for COVID-19	0.453	1
	COVID-19 severity	0.784	1
	SARS-CoV-2 variant	0.342	1
	Timing of COVID-19 (trimester)	0.303	1
High grade chronic	COVID-19 at delivery	0.419	1
inflammation	Treatment for COVID-19	0.917	1
Innammation	COVID-19 severity	0.100	0.501
	SARS-CoV-2 variant	0.898	1
	Timing of COVID-19 (trimester)	0.592	1
Chronic histiocytic	COVID-19 at delivery	0.196	0.982
intervillositis or high grade	Treatment for COVID-19	0.965	1
chronic villitis	COVID-19 severity	0.014	0.069
	SARS-CoV-2 variant	0.926	1

512

¹Bonferroni adjustment for five potential predictors to minimize chances of a Type 1 error.